

- --- Intravenous EPOGEN
- → Subcutaneous EPOGEN
- Subcutaneous MR-NGE
- → Intravenous MR-NGE

FIG. 3A






FIG. 3B



SUBSTITUTE SHEET (RULE 26)







FIG. 5



SUBSTITUTE SHEET (RULE 26)

BEST AVAILABLE COPY

FIG. 6A





FIG. 6B



SUBSTITUTE SHEET (RULE 26)

FIG. 6C







FIG. 6D



SUBSTITUTE SHEET (RULE 26)

FIG. 7A





SUBSTITUTE SHEET (RULE 26)

FIG. 8






FIG. 9A



 $log(U/mg)=5.48(\pm 0.10)-0.55(\pm 0.04)$ Degree of PEGylation intercept: Prob>[t]<0.0001 slope: Prob>[t]<0.0001

 $R^2:0.92$

FIG. 9B




log(U/mg)=5.41-0.63 Degree of PEGylation

intercept: Prob>[t]<0.0001 slope: Prob>[t]<0.0001


R²:0.75

FIG. 10




- ▲ 100 ug/kg, s.c. dose
 □ 50 ug/kg, s.c. dose
 ◆ 20 ug/kg, s.c. dose

FIG. 11




- 20 ug/kg, s.c. dose 50 ug/kg, s.c. dose
- 100 ug/kg, s.c. dose



- \diamondsuit Cmpd AM [PEG(20kDa)_{3.3}]
- ▲ Cmpd F [PEG(20kDa)_{2.5}]
- ☐ Cmpd G [PEG(20kDa)_{2.1}]
- ▼ Cmpd Z [PEG(20kDa)_{1.0}]
- O Cmpd Epo

FIG. 13



PBS/BSA Epo AM

